| scholarly article | Q13442814 |
| P50 | author | Peter Buggisch | Q47155906 |
| Robert Flisiak | Q56980311 | ||
| Patrick Marcellin | Q89798262 | ||
| Maria Buti | Q91265862 | ||
| P2093 | author name string | Jane Anderson | |
| E Jenny Heathcote | |||
| Robert A De Man | |||
| Michael Manns | |||
| George Germanidis | |||
| Peter Buggisch | |||
| Samuel S Lee | |||
| Frank Weilert | |||
| Edward Gane | |||
| Mitchell L Shiffman | |||
| Elsa Mondou | |||
| Franck Rousseau | |||
| Iskren Kotzev | |||
| Kelly Kaita | |||
| Katyna Borroto-Esoda | |||
| Selim Gurel | |||
| Huy Trinh | |||
| Jeff Sorbel | |||
| Zahary Krastev | |||
| Andrea Snow-Lampart | |||
| Oya Ovunc Kurdas | |||
| Konstantin Tchernev | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tenofovir | Q155954 |
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 132-143 | |
| P577 | publication date | 2010-10-16 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. | |
| P478 | volume | 140 |
| Q42713114 | 9-[2-(R)-(Phosphonomethoxy)propyl]-2,6-diaminopurine (R)-PMPDAP and its prodrugs: optimized preparation, including identification of by-products formed, and antiviral evaluation in vitro |
| Q40318439 | A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy |
| Q33711399 | A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women |
| Q34036018 | A cutting-edge view on the current state of antiviral drug development |
| Q44766209 | A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. |
| Q40729465 | A pregnant woman with acute hepatitis B in whom vertical transmission was prevented by tenofovir disoproxil fumarate |
| Q92637463 | A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48 |
| Q42192860 | A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. |
| Q34501660 | AASLD guidelines for treatment of chronic hepatitis B. |
| Q37975548 | Adefovir dipivoxil in chronic hepatitis B: history and current uses |
| Q35906015 | Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B. |
| Q37651892 | Adverse effects of oral antiviral therapy in chronic hepatitis B. |
| Q37201993 | An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation |
| Q52685884 | An expert consensus for the management of chronic hepatitis B in Asian Americans. |
| Q26782742 | Anti-HBV Drugs: Progress, Unmet Needs, and New Hope |
| Q40196246 | Antibody-mediated immunotherapy against chronic hepatitis B virus infection |
| Q47568387 | Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B. |
| Q40484179 | Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection |
| Q36606780 | Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone |
| Q35245231 | Antiviral therapies and prospects for a cure of chronic hepatitis B. |
| Q35840548 | Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis |
| Q30391932 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. |
| Q35706189 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update |
| Q42259021 | Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. |
| Q33845546 | Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients |
| Q37165176 | CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study |
| Q40841454 | Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy |
| Q34137291 | Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit |
| Q36769986 | Chronic hepatitis B: what should be the goal for new therapies? |
| Q46501449 | Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study |
| Q34797281 | Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B. |
| Q37994049 | Clinical implications of HBsAg quantification in patients with chronic hepatitis B. |
| Q51643325 | Clinical trials and their translation in hepatology: past, present, and future. |
| Q84598386 | Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review |
| Q37866717 | Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review |
| Q36973383 | Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. |
| Q37178556 | Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study |
| Q35739079 | Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus. |
| Q28539472 | Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis |
| Q36449625 | Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis |
| Q35173563 | Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in China |
| Q36492635 | Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis |
| Q61806190 | Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials |
| Q99616718 | Complex genetic encoding of the hepatitis B virus on-drug persistence |
| Q39121074 | Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China |
| Q28550643 | Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China |
| Q35535861 | Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety |
| Q37934571 | Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. |
| Q26851240 | Current and future directions for treating hepatitis B virus infection |
| Q38208628 | Current developments in nucleoside/nucleotide analogues for hepatitis B. |
| Q93136810 | Current perspectives into the evaluation and management of hepatitis B: a review |
| Q38553056 | Current treatment of hepatitis B virus infections |
| Q37274697 | Design of therapeutic vaccines: hepatitis B as an example |
| Q46107250 | Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis |
| Q27022216 | Direct acting antivirals for the treatment of chronic viral hepatitis |
| Q92466235 | Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B |
| Q36797804 | Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy |
| Q45352198 | Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs |
| Q37690134 | Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B. |
| Q50003421 | Effect of tenofovir on renal function in patients with chronic hepatitis B. |
| Q40245207 | Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hep |
| Q40313106 | Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany |
| Q37250436 | Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France |
| Q40145207 | Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis |
| Q36686179 | Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA |
| Q36745002 | Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. |
| Q40675705 | Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial |
| Q37439967 | Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection |
| Q33829957 | Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load |
| Q28468387 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience |
| Q58803118 | Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries |
| Q37564039 | Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. |
| Q59357110 | Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study) |
| Q26765932 | Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis |
| Q40555175 | Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs |
| Q41349327 | Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus |
| Q41645626 | Efficacy of tenofovir disoproxil fumarate therapy in Chinese chronic hepatitis B patients after multiple antiviral failures |
| Q35671645 | Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B. |
| Q36698116 | Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study |
| Q37135543 | Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay |
| Q42279462 | Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate. |
| Q40832139 | Favorable outcome of extended treatment with adding pegylated Interferonα-2a to entecavir for HBeAg-positive chronic hepatitis B: a case report |
| Q90369207 | First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China |
| Q46243261 | Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. |
| Q93082039 | Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis |
| Q36950984 | GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees |
| Q36255419 | HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis |
| Q41986565 | HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients. |
| Q52632456 | HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. |
| Q37614037 | HBsAg Quantification in Clinical Practice |
| Q41718138 | HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy |
| Q38295840 | HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients |
| Q38174257 | HBsAg quantification: useful for monitoring natural history and treatment outcome |
| Q40707587 | HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study |
| Q42201273 | HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy. |
| Q58376622 | Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV |
| Q58235686 | Hepatitis B Surface Antigen Seroclearance: Relationship to Hepatitis B e-Antigen Seroclearance and Hepatitis B e-Antigen-Negative Hepatitis |
| Q59103430 | Hepatitis B Virus Infection and the Kidney: Renal Abnormalities in HBV Patients, Antiviral Drugs Handling, and Specific Follow-Up |
| Q34384793 | Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection |
| Q35891425 | Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients |
| Q40172735 | Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study |
| Q37892655 | Hepatitis B surface antigen monitoring and management of chronic hepatitis B. |
| Q41249783 | Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. |
| Q35663838 | Hepatitis B virus genotypes and variants. |
| Q38365905 | Hepatitis B virus infection in children |
| Q93080857 | Hepatitis B virus infection in children and adolescents |
| Q55380360 | Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA. |
| Q37966704 | Hepatitis B virus serology to predict antiviral response in chronic hepatitis B. |
| Q34257596 | Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs |
| Q36883851 | Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection |
| Q40136236 | Impact of deletions and mutations in Hepatitis B virus envelope proteins on serological profile and clinical evolution. |
| Q40733311 | Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. |
| Q38071395 | Impact of therapy on the outcome of chronic hepatitis B. |
| Q38252962 | Improving clinical outcomes of chronic hepatitis B virus infection. |
| Q38260502 | Incidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis |
| Q58750557 | Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9 |
| Q28073697 | Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis |
| Q46037099 | Interleukin-18 facilitates neutrophil transmigration via myosin light chain kinase-dependent disruption of occludin, without altering epithelial permeability. |
| Q40385406 | Is increasing the dose of Entecavir effective in partial virological responders? |
| Q26752475 | KASL clinical practice guidelines: management of chronic hepatitis B |
| Q40749549 | Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients |
| Q35288973 | Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years |
| Q34948124 | Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients |
| Q42180462 | Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting |
| Q41719578 | Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients. |
| Q36172270 | Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen. |
| Q40668632 | Long-term lamivudine therapy in chronic hepatitis B. |
| Q38097858 | Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal |
| Q42235230 | Loss of HBsAg and antiviral treatment: from basics to clinical significance |
| Q36505336 | Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment. |
| Q27008984 | Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments |
| Q38008173 | Management of rheumatic disease with comorbid HBV or HCV infection. |
| Q51873464 | Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. |
| Q38219020 | Molecular diagnosis and treatment of drug-resistant hepatitis B virus |
| Q38594605 | Monotherapy for hepatitis B infection: a review of treatment options |
| Q38955049 | Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. |
| Q35864595 | Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand |
| Q59350183 | New and Old Biomarkers for Diagnosis and Management of Chronic HBV Infection |
| Q38174265 | New therapeutic perspectives in HBV: when to stop NAs. |
| Q38725759 | New therapies for chronic hepatitis B. |
| Q40433318 | Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release |
| Q42277100 | No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. |
| Q39431420 | Nucleos(t)ide analogues for the prevention of hepatitis B recurrence after liver transplantation do not affect serum phosphorus levels. |
| Q27030828 | Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B |
| Q37482902 | On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B |
| Q38071396 | Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. |
| Q38295850 | Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? |
| Q27020938 | Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors |
| Q41208197 | Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression |
| Q90755927 | Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus |
| Q37381790 | Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B |
| Q45356906 | Prevention and management of drug resistant hepatitis B virus infections. |
| Q57491223 | Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA |
| Q35960972 | Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response |
| Q34674838 | Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals |
| Q41505915 | Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence? |
| Q30394611 | Recent advances in micro/nanotechnologies for global control of hepatitis B infection |
| Q38333875 | Recent advances in prevention of hepatitis B recurrence after liver transplantation |
| Q59306519 | Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B |
| Q58235736 | Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy |
| Q34317204 | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study |
| Q42257926 | Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir |
| Q42223321 | Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment |
| Q47787500 | Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection |
| Q39220767 | Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting |
| Q36238754 | Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B |
| Q38168296 | Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease |
| Q38177252 | Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation |
| Q36445048 | Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents |
| Q91841898 | Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials |
| Q43547497 | Scar undone: long-term therapy of hepatitis B. |
| Q58376653 | Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss |
| Q38224440 | Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues |
| Q40543517 | Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. |
| Q39328124 | Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma |
| Q37372998 | Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report |
| Q34308129 | Strategies to eliminate HBV infection |
| Q44973263 | Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation |
| Q47598112 | Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance |
| Q36254363 | Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial |
| Q50181120 | Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection |
| Q59356224 | Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence |
| Q45357942 | Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series |
| Q46044243 | Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. |
| Q38038690 | Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. |
| Q35152367 | Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients |
| Q30860824 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. |
| Q35105892 | Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B |
| Q42159733 | Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures |
| Q36492640 | Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures |
| Q36067839 | Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases |
| Q44966178 | Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation |
| Q38009758 | Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)? |
| Q42245777 | The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. |
| Q26781795 | The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs |
| Q38520954 | The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists |
| Q36189795 | The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country |
| Q37284974 | The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4(+)CD25(+) regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment |
| Q37936321 | The management of chronic hepatitis B in Asian Americans |
| Q38071397 | The role of HBsAg quantification for monitoring natural history and treatment outcome |
| Q46623464 | The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. |
| Q45073764 | Third-trimester tenofovir to prevent mother-to-child hepatitis B virus transmission |
| Q40835942 | Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients |
| Q37600575 | Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea |
| Q38071400 | Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues |
| Q37620340 | Treatment of Hepatitis B: A Concise Review |
| Q38223361 | Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. |
| Q28066476 | Treatment strategies according to genotype for chronic hepatitis B in children |
| Q47136128 | Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? |
| Q50190669 | Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance |
| Q38259535 | Update on hepatitis B virus infection |
| Q38033446 | Update on tenofovir toxicity in the kidney |
| Q41549327 | Use of nucleoside analogs in patients with chronic hepatitis B in Nepal: A prospective cohort study in a single hospital |
| Q38217668 | Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women |
| Q48265626 | Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. |
| Q42194740 | Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. |
| Q33857643 | Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir |
| Q35681979 | Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients |
| Q38685589 | Virological and serological tools to optimize the management of patients with chronic hepatitis B. |
| Q26864647 | Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation |
Search more.